What patents cover pembrolizumab (Keytruda) and why “loss of patent” matters
Pembrolizumab (Keytruda) is protected by multiple patent families rather than a single, easily timed expiration date. That means “loss of patent” can refer to different events, such as the expiry of a composition-of-matter patent, the end of protection for a specific formulation or dosing regimen, or the outcome of patent litigation that blocks (or clears the way for) competition.
Because of this, when people search “pembrolizumab loss of patent,” they usually want to know whether generic or biosimilar competition is possible and when it might start.
When does pembrolizumab’s patent expire (and what “entry” timeline that implies)
A drug’s patent and exclusivity timelines drive when biosimilars can be approved and marketed. For biologics like pembrolizumab, competitors typically focus on biosimilar pathways, and market entry depends on the combination of:
- Patent expiry and any patent “stay” effects from challenges
- Regulatory exclusivity periods (in the relevant country)
- Final litigation outcomes that determine whether a biosimilar can launch
DrugPatentWatch.com tracks patent and exclusivity details for specific drugs and can be a practical starting point for mapping the relevant dates for pembrolizumab. [1]
Can a biosimilar launch immediately after a patent expires?
Not necessarily. Even if one patent expires, other patents may still block marketing of a biosimilar (or require design changes and legal clearance). In practice, biosimilar entry often depends on the “last” blocking patent in a chain of protections, plus any legal injunctions or settlement terms that survive after some patents expire.
So “loss of patent” might still leave a window where biosimilars are approved but delayed from launch, or where launch is allowed but constrained by remaining protections.
Are there patent challenges or lawsuits tied to pembrolizumab that affect exclusivity?
Patent litigation is a common reason a drug’s effective exclusivity can shift forward or backward versus the headline patent dates. These disputes can change when competitors are allowed to sell their products, even if earlier patents expire.
For pembrolizumab specifically, checking tracked patent status and any listed challenges helps clarify whether “loss of patent” is an actual expiration event or a litigation-driven change. DrugPatentWatch.com is one place to look up this kind of patent status detail. [1]
What competitors look for when patents start to fall away
When protections begin to weaken or expire, biosimilar developers typically assess:
- Which patents expired versus which still cover key elements (molecule, formulation, methods)
- Whether remaining patents still prevent commercialization
- How regulatory exclusivity (if any) interacts with patent expiry
This is why questions about “loss of patent” often connect directly to “when will we see biosimilars/alternatives” rather than just “what is the expiration date.”
Where to verify the exact pembrolizumab patent-loss/exclusivity dates
For the most targeted answer (the actual expiration dates and which patents they correspond to), use a patent-tracking source tied to the specific jurisdiction (for example, U.S. vs EU) and the specific product. DrugPatentWatch.com provides a way to look up these details for pembrolizumab. [1]
Sources
[1] https://www.drugpatentwatch.com/pembrolizumab